Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-06-07
1998-07-28
Robinson, Douglas W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
4351723, 4353201, 435325, 536 235, 536 245, A61K 4800, C07H 2104, C12N 1512, C12N 1585
Patent
active
057863415
ABSTRACT:
Methods are provided for controlling the synthesis of protein from the human gene for the pro.alpha.1(I) chain of type I procollagen in cells using mini-gene constructs which are injected into cells which synthesize the protein. Methods for controlling collagen deposition in tissue mini-gene constructs are also provided.
REFERENCES:
patent: 4736866 (1988-04-01), Leder et al.
Ala-Kokko et al., "Hepatic Fibrosis in Rats Produced by Carbon Tetrachloride and Dimethylnitrosamine: Observations Suggesting Immunoassays of Serum for the 7S Fragment of Ype IV Collagen area More Sensitive Index of Liver Damage than Immunoassays for the NH.sub.2 -Terminal Propeptide of Type III Procollagen", Hapatology 16:167-172 (1992).
Ala-Kokko et al., "Single base mutation in the type II procollagen gene (COL2A1) as a cause of primary osteoarthritis associated with a mild chondrodysplasia", Proc. Natl. Acad. Sci, USA 87:6565-6568 (1990).
Bonadio et al, "Transgenic mouse model of the mild dominant form of osteogenesis imperfecta", Proc. Natl. Acad. Sci, USA 87:6565-6568 (1990).
Byers, "Brittle bones--fragile molecules: disorders of collagen gen structure and expression", TIG 6:293-300 (1990).
Chang et al., "Antisense Inhibition of ras p21 Expression that is Sensitive to a Point Mutation", Biochemistry 30:8283-8286 (1991).
Chiang et al., "Antisense Oligonucleotides Inhibit Intercellular Adhesion Molecule 1 Expression by Two Distinct Mechanisms", J. Biol. Chem. 266:18162-18171 (1991).
Chomcynski et al., "Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction", Anat. Biochem. 162:156-159 (1987).
Chu et al., Connective Tissue and Its Heritable Disorders, Chapter 3, Part II, pp. 249-265 (1993).
Khillan et al., "Transgenic Mice That Express a Mini-gene Version of the Human Gene for Type I Procollagen (COL1A1) Develop a Phenotype Resembling a Lethal Form of Osteogenesis Imperfecta", J. Biol. Chem. 266:23373-23379 (1991).
Kole et al., "Pre-mRNA splicing as a target for antisense oligonucleotides", Adv. Drug Del. Rev. 6:271-286 (1991).
Kuivaniemi et al., "Mutations in collagen genes: causes of rare and some common diseases in humans", FASEB J. 5:2052-2060 (1991).
Marmur et al., "Determination of the Base Composition of Deoxyribonucleic Acid from it Thermal Denaturation Temperature", J. Mol. Biol. 5:109-118 (1962).
Mooslehner et al., "Two mRNAs of mouse pro .alpha.1(I) collagen gene differ in the size of the 3'-untranslated region", Nucleic Acids Research 16:773 (1988).
Munroe, "Antisense RNA inhibits splicing of pre-mRNA in vitro", EMBO J. 7:2523-2532 (1988).
Myers et al., "Cloning a cDNA for the pro-.alpha.2 chain of human type I collagen", Proc. Natl. Acad. Sci USA 78:3516-3520 (1981).
Olsen et al., "High Levels of Expression of a Minigene Version of the human Pro.alpha.1(I) Collagen Gene in Stably Transfected Mouse Fibroblasts", J. Biol. Chem 266:1117-1121 (1991).
Orkin, The Molecular Basis of Blood Diseases, G. Stamatoyannopoulous et al. Eds., W.B. Saunders, Philadelphia, pp. 106-126 (1987).
Prockop et al., Ann N.Y. Acad. Sci, vol. 580, (1990) pp. 330-339.
Prockop, "Minireview: Mutations That Alter the Primary Structure of Type I Collagen", J. Biol. Chem. 265:15349-15352 (1990).
Slack et al., "An Upstream Regulatory Region Mediates High-Level,Tissue-Specific Expression of the Human .alpha.1(I) Collagen Gene in Transgenic Mice", Molecular and Cellular Biology, Apr. 1991, pp. 2066-2074.
Stacy et al., Perinatal lethal osteogenesis imperfecta in transgenic mice bearing an engineered mutant pro-.alpha.1 (I) collagen gene, Nature 332:131-136 (1988).
Stein et al., "Oligodeoxynucleotides as Inhibitors of Gene Expression: A Review", Cancer Research 48:2659-2668 (1988).
Sykes, "Bone disease cracks genetics", Nature 348:18-20 (1990).
Vanderberg et al., "Expression of a partially deleted gene of human type II procollagen (COL2A1)", Proc. Natl. Acad. Sci 88:7640-7644 (1991).
Vu et al., "Internucleotide Phosphite Sulfurization with Tetraethylthiuram Disulfide, Phosphorothioate Oligonucleotide Synthesis Via Phophoramidite Chemistry", Tetrahedron Letters 32:3005-3008 (1991).
Vuorio et al., J. Cell. Biochem. Supp. 15A (Jan. 1991) p. 205, Abstract No. B423.
Westerhausen et al., "Completion of the Last Half of the Structure of the Human Gene for the Pro.alpha.1(I) Chain of Type I Procollagen (COL1A1)", Matrix 11:375-379 (1991).
Williams et al., "Synthesis and Processing of a Type I Procollagen Containing Shortened Pro-.alpha.1(I) Chains by Fibroblasts form a Patent with Osteogenesis Imperfecta", J. Biol. Chem. 258:5915-5921 (1983).
Wu et al., "Human-Mouse Interspecies Collagen I Heterotrimer Is Functional During Embryonic Development of Mov13 Mutant Mouse Embryos", Molecular and Cellular Biology 10:1452-1460 (1990).
Uhlmann et al., "Antisense Oligonucleotides: a new therapeutic principle," Chemical Reviews 90(4):544-579 (1990).
Nussbaum et al., Abstract No. 1505, 42nd Annual Meeting, San Francisco, CA, The American Society of Human Genetics, Nov. 9-13, 1992.
Wickstrom, "Strategies for administering targeted therapeutic oligodeoxynucleotides", Tibtech 10:281-287 (1992).
Ledley et al., "Clinical considerations in the design of protocols for somatic gene therapy", Human Gene Therapy 2:77-83 (1991).
Prockop et al., Ann. of the NY Acad. of Sci. 580:330-339 (1990).
Stull RA, et al. "Antigene, ribozyme and aptamer nucleic acid drugs: Progress and prospects." Pharmaceutical Research 12 (4): 465-483., 1995.
Orkin SH, et al. "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy.", Dec. 7, 1995.
Khillan Jaspal
Li Shi-Wu
Pereira Ruth
Prockop Darwin J.
Nelson Amy J.
Robinson Douglas W.
Thomas Jefferson University
LandOfFree
Use of a COL1A1 mini-gene construct to inhibit collagen synthesi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of a COL1A1 mini-gene construct to inhibit collagen synthesi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of a COL1A1 mini-gene construct to inhibit collagen synthesi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-23699